Successful management of an infant with a giant hemangioma of the retroperitoneum and Kasabach-Merritt Syndrome with α-interferon

R. M. Hatley, H. Sabio, C. G. Howell, F. Flickinger, R. A. Parrish

Research output: Contribution to journalArticle

51 Scopus citations

Abstract

Giant vascular neoplasms in neonates generally require aggressive medical or surgical therapy for treatment of complications. Steroids, chemotherapy, embolization, radiation, and surgery have all been used with short-term beneficial and sometimes unknown long-term side effects. A new modality of treatment, α-interferon, has recently been described. The majority of hemangiomas in children involtute by 8 years of age. Occasionally, hemangiomas can endanger vital structures and are associated with a consumption coagulopathy and thrombocytopenia (Kasabach-Merritt Syndrome). These hemangiomas occasionally do not respond to steroids, radiation therapy, cytotoxic drugs, or embolization. The mortality rates approach 50% in nonresponders. Alphainterferon has been used in these children with life-threatening complications of hemangiomas with relief of symptoms. This case illustrates the potential use of α-interferon in the management of giant hemangiomas in children. This emerging form of biological therapy avoids the risks of radiation therapy, embolization, and surgery with only minimal side effects.

Original languageEnglish (US)
Pages (from-to)1356-1359
Number of pages4
JournalJournal of Pediatric Surgery
Volume28
Issue number10
DOIs
StatePublished - Oct 1993
Externally publishedYes

Keywords

  • Hemangioma
  • Kasabach-Merritt syndrome
  • α-interferon

ASJC Scopus subject areas

  • Surgery
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Successful management of an infant with a giant hemangioma of the retroperitoneum and Kasabach-Merritt Syndrome with α-interferon'. Together they form a unique fingerprint.

  • Cite this